

In the format provided by the authors and unedited.

# CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy

Amira A. Barkal<sup>1,2,3,4</sup>, Rachel E. Brewer<sup>1,2,3</sup>, Maxim Markovic<sup>1,2,3</sup>, Mark Kowarsky<sup>5</sup>, Sammy A. Barkal<sup>1</sup>, Balyn W. Zaro<sup>1,2,3</sup>, Venkatesh Krishnan<sup>6</sup>, Jason Hatakeyama<sup>1,7</sup>, Oliver Dorigo<sup>6</sup>, Layla J. Barkal<sup>8</sup> & Irving L. Weissman<sup>1,2,3,9\*</sup>

<sup>1</sup>Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, USA. <sup>2</sup>Ludwig Center for Cancer Stem Cell Research and Medicine, Stanford University School of Medicine, Stanford, CA, USA. <sup>3</sup>Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA. <sup>4</sup>Stanford Medical Scientist Training Program, Stanford University, Stanford, CA, USA. <sup>5</sup>Department of Physics, Stanford University, Stanford, CA, USA. <sup>6</sup>Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Stanford University School of Medicine, Stanford, CA, USA. <sup>7</sup>Department of Urology, Stanford University School of Medicine, Stanford, CA, USA. <sup>8</sup>Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA. <sup>9</sup>Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA. \*e-mail: [irv@stanford.edu](mailto:irv@stanford.edu)

**Supplementary Table 1.** Data table including abbreviated names, full names, and tumor vs. healthy *n* for TCGA, TARGET, and GTEX studies analyzed for this work

<b>TCGA Study Abbreviation</b>	<b>TCGA or TARGET Study Name</b>	<b>GTEX Study Name(s)</b>	<b>Patient tumors analyzed (n)</b>	<b>Healthy samples analyzed (n)</b>
OV	Ovarian serous cystadenocarcinoma	Ovary	419	88
CHOL	Cholangiocarcinoma	N/A (only TCGA normal)	36	9
TGCT	Testicular germ cell tumors	Testis	148	165
LGG	Lower grade glioma	Brain - cortex	509	105
BRCA	Breast invasive carcinoma	Breast	1092	292
CESC	Cervical squamous cell and endocervical adenocarcinoma	Endocervix, Ectocervix	304	13
UCEC	Uterine corpus endometrial carcinoma	N/A (only TCGA normal)	180	23
ALL	Acute lymphoblastic leukemia (peripheral blood)	Whole blood	37	337
BLCA	Bladder urothelial carcinoma	Bladder	407	28
STAD	Stomach adenocarcinoma	Stomach	414	211
GBM	Glioblastoma multiforme	Brain - cortex	153	110
LIHC	Liver hepatocellular carcinoma	Liver	369	160
PRAD	Prostate adenocarcinoma	Prostate	495	152
LUSC	Lung squamous cell carcinoma	Lung	498	50
LUAD	Lung adenocarcinoma	Lung	513	59
KIRP	Kidney renal papillary cell carcinoma	Kidney	288	32
CCSK	Clear cell sarcoma of the kidney (TARGET)	Kidney	13	28
THCA	Thyroid carcinoma	Thyroid	504	338
KIRC	Kidney renal clear cell carcinoma (TCGA)	Kidney	530	72
ESCA	Esophageal carcinoma	Esophagus	181	13
READ	Rectum adenocarcinoma	N/A (only TCGA normal)	92	11
DLBCL	Diffuse large B cell lymphoma	Whole blood	48	337
COAD	Colon adenocarcinoma	Colon - sigmoid, Colon - transverse	288	41
PAAD	Pancreatic adenocarcinoma	Pancreas	178	171
KICH	Kidney chromophobe	Kidney	66	25
HNSC	Head and neck squamous cell carcinoma	N/A (only TCGA normal)	518	44
ACC	Adrenocortical carcinoma	Adrenal gland	77	128
AML	Acute Myeloid Leukemia	Whole blood	200	337

**Supplementary Table 2.** Data table including clone, use, and supplier for all antibodies used in this work

<b>Antibody</b>	<b>Clone</b>	<b>Use</b>	<b>Supplier</b>
Anti-human CD24	SN3 (conjugated)	FACS	Novus Bio, Thermo Fisher Scientific
	SN3 (unconjugated)	Treatment	Novus Bio
Anti-human Siglec-10	5G6 (conjugated)	FACS	BioLegend
	5G6 (unconjugated)	Treatment	BioLegend
Mouse IgG1 Isotype Control	MOPC-21 (conjugated)	FACS	BioLegend
	MOPC-21 (unconjugated)	Treatment	BioXCell
Anti-human CD47	B6H12	FACS	BioLegend
	5F9-G4	Treatment	In house
Anti-human Fc	HP6017	FACS	BioLegend
Anti-human EGFR	Cetuximab	Treatment	Bristol-Myers-Squibb
Human IgG4 Isotype Control	ET904	Treatment	Eureka Therapeutics
Human IgG1 Isotype Control	N/A (Cat #: BE0297)	Treatment/FACS	BioXCell
Anti-human CD14	M5E2	FACS	BioLegend
Anti-human CD45	HI30	FACS	BioLegend
Anti-human/mouse CD11b	M1/70	FACS	BioLegend
Anti-mouse CD80	16-10A1	FACS	BioLegend
Anti-human EpCAM	9C4	FACS	BioLegend
Anti-human CD56	HCD56	FACS	BioLegend
Anti-human CD3	UCHT1	FACS	BioLegend
Anti-human CD19	SJ25C1	FACS	BioLegend
Anti-human Siglec-5	1A5	FACS	BioLegend
Anti-human Siglec-9	K8	FACS	BioLegend
Anti-mouse CD45	30-F11	FACS	BioLegend
Anti-mouse F4/80	BM8	FACS	BioLegend
Anti-mouse CD24a	M1/69	FACS	BioLegend
Anti-mouse CSFR1	AFS98	Treatment	BioXCell